These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 24828264)

  • 1. Identifying the survival subtypes of glioblastoma by quantitative volumetric analysis of MRI.
    Zhang Z; Jiang H; Chen X; Bai J; Cui Y; Ren X; Chen X; Wang J; Zeng W; Lin S
    J Neurooncol; 2014 Aug; 119(1):207-14. PubMed ID: 24828264
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quantitative volumetric assessment of baseline enhancing tumor volume as an imaging biomarker predicts overall survival in patients with glioblastoma.
    Auer TA; Della Seta M; Collettini F; Chapiro J; Zschaeck S; Ghadjar P; Badakhshi H; Florange J; Hamm B; Budach V; Kaul D
    Acta Radiol; 2021 Sep; 62(9):1200-1207. PubMed ID: 32938221
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Apparent diffusion coefficient and tumor volume measurements help stratify progression-free survival of bevacizumab-treated patients with recurrent glioblastoma multiforme.
    Buemi F; Guzzardi G; Del Sette B; Sponghini AP; Matheoud R; Soligo E; Trisoglio A; Carriero A; Stecco A
    Neuroradiol J; 2019 Aug; 32(4):241-249. PubMed ID: 31066622
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical parameters outweigh diffusion- and perfusion-derived MRI parameters in predicting survival in newly diagnosed glioblastoma.
    Burth S; Kickingereder P; Eidel O; Tichy D; Bonekamp D; Weberling L; Wick A; Löw S; Hertenstein A; Nowosielski M; Schlemmer HP; Wick W; Bendszus M; Radbruch A
    Neuro Oncol; 2016 Dec; 18(12):1673-1679. PubMed ID: 27298312
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prediction of survival with multi-scale radiomic analysis in glioblastoma patients.
    Chaddad A; Sabri S; Niazi T; Abdulkarim B
    Med Biol Eng Comput; 2018 Dec; 56(12):2287-2300. PubMed ID: 29915951
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Multicenter imaging outcomes study of The Cancer Genome Atlas glioblastoma patient cohort: imaging predictors of overall and progression-free survival.
    Wangaryattawanich P; Hatami M; Wang J; Thomas G; Flanders A; Kirby J; Wintermark M; Huang ES; Bakhtiari AS; Luedi MM; Hashmi SS; Rubin DL; Chen JY; Hwang SN; Freymann J; Holder CA; Zinn PO; Colen RR
    Neuro Oncol; 2015 Nov; 17(11):1525-37. PubMed ID: 26203066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of heterogeneity of peritumoral T2 hyperintensity in patients with pretreatment glioblastoma: Prognostic value of MRI-based radiomics.
    Choi Y; Ahn KJ; Nam Y; Jang J; Shin NY; Choi HS; Jung SL; Kim BS
    Eur J Radiol; 2019 Nov; 120():108642. PubMed ID: 31546124
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of Dynamic Contrast-Enhanced MRI-Derived Pharmacokinetic Variables in Glioblastoma Patients: Analysis of Contrast-Enhancing Lesions and Non-Enhancing T2 High-Signal Intensity Lesions.
    Kang Y; Hong EK; Rhim JH; Yoo RE; Kang KM; Yun TJ; Kim JH; Sohn CH; Park SW; Choi SH
    Korean J Radiol; 2020 Jun; 21(6):707-716. PubMed ID: 32410409
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Identifying the mesenchymal molecular subtype of glioblastoma using quantitative volumetric analysis of anatomic magnetic resonance images.
    Naeini KM; Pope WB; Cloughesy TF; Harris RJ; Lai A; Eskin A; Chowdhury R; Phillips HS; Nghiemphu PL; Behbahanian Y; Ellingson BM
    Neuro Oncol; 2013 May; 15(5):626-34. PubMed ID: 23444259
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Survival analysis in patients with newly diagnosed primary glioblastoma multiforme using pre- and post-treatment peritumoral perfusion imaging parameters.
    Bag AK; Cezayirli PC; Davenport JJ; Gaddikeri S; Fathallah-Shaykh HM; Cantor A; Han XS; Nabors LB
    J Neurooncol; 2014 Nov; 120(2):361-70. PubMed ID: 25098699
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Volumetric and MGMT parameters in glioblastoma patients: survival analysis.
    Iliadis G; Kotoula V; Chatzisotiriou A; Televantou D; Eleftheraki AG; Lambaki S; Misailidou D; Selviaridis P; Fountzilas G
    BMC Cancer; 2012 Jan; 12():3. PubMed ID: 22214427
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Early post-bevacizumab progression on contrast-enhanced MRI as a prognostic marker for overall survival in recurrent glioblastoma: results from the ACRIN 6677/RTOG 0625 Central Reader Study.
    Boxerman JL; Zhang Z; Safriel Y; Larvie M; Snyder BS; Jain R; Chi TL; Sorensen AG; Gilbert MR; Barboriak DP
    Neuro Oncol; 2013 Jul; 15(7):945-54. PubMed ID: 23788270
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Ventricle contact is associated with lower survival and increased peritumoral perfusion in glioblastoma.
    van Dijken BRJ; Jan van Laar P; Li C; Yan JL; Boonzaier NR; Price SJ; ; van der Hoorn A
    J Neurosurg; 2018 Oct; 131(3):717-723. PubMed ID: 30485234
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo.
    Ellingson BM; Abrey LE; Garcia J; Chinot O; Wick W; Saran F; Nishikawa R; Henriksson R; Mason WP; Harris RJ; Leu K; Woodworth DC; Mehta A; Raymond C; Chakhoyan A; Pope WB; Cloughesy TF
    Neuro Oncol; 2018 Oct; 20(11):1525-1535. PubMed ID: 29897562
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic factors in patients with glioblastoma multiforme: focus on the pathologic variants.
    Alimohammadi E; Bagheri SR; Sadeghsalehi A; Rizevandi P; Rezaie Z; Abdi A
    Acta Neurol Belg; 2020 Dec; 120(6):1341-1350. PubMed ID: 31222512
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Survival of glioblastoma treated with a moderately escalated radiation dose-Results of a retrospective analysis.
    Shieh LT; Guo HR; Ho CH; Lin LC; Chang CH; Ho SY
    PLoS One; 2020; 15(5):e0233188. PubMed ID: 32413077
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Glioblastoma: does the pre-treatment geometry matter? A postcontrast T1 MRI-based study.
    Pérez-Beteta J; Martínez-González A; Molina D; Amo-Salas M; Luque B; Arregui E; Calvo M; Borrás JM; López C; Claramonte M; Barcia JA; Iglesias L; Avecillas J; Albillo D; Navarro M; Villanueva JM; Paniagua JC; Martino J; Velásquez C; Asenjo B; Benavides M; Herruzo I; Delgado MD; Del Valle A; Falkov A; Schucht P; Arana E; Pérez-Romasanta L; Pérez-García VM
    Eur Radiol; 2017 Mar; 27(3):1096-1104. PubMed ID: 27329522
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Carbonic anhydrase IX is a prognostic biomarker in glioblastoma multiforme.
    Cetin B; Gonul II; Gumusay O; Bilgetekin I; Algin E; Ozet A; Uner A
    Neuropathology; 2018 Oct; 38(5):457-462. PubMed ID: 29952031
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recurrent glioblastoma: volumetric assessment and stratification of patient survival with early posttreatment magnetic resonance imaging in patients treated with bevacizumab.
    Huang RY; Rahman R; Hamdan A; Kane C; Chen C; Norden AD; Reardon DA; Mukundun S; Wen PY
    Cancer; 2013 Oct; 119(19):3479-88. PubMed ID: 23821555
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pre-Operative Perfusion Skewness and Kurtosis Are Potential Predictors of Progression-Free Survival after Partial Resection of Newly Diagnosed Glioblastoma.
    Paik W; Kim HS; Choi CG; Kim SJ
    Korean J Radiol; 2016; 17(1):117-26. PubMed ID: 26798224
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.